Trade Summary

Yesterday, Karydas Daphne, serving as Dir at Mineralys Therapeutics, Inc. (MLYS), sold 3,000 shares at $25.00 per share, for a total transaction value of $75,000.00. Following this transaction, Karydas Daphne now holds 6,200 shares of MLYS.

This sale represents a 32.61% decrease in Karydas Daphne's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, June 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, June 18, 2026 (accepted Jun 17, 9:18 PM ET), 1 day after the trade was made.

Mineralys Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.